Loading
Loading
Metabolic & Body Composition · 5mg + 5mg
Choose dose
10 vials per kit
Cagrisema is a research peptide combination of Cagrilintide 5mg and Semaglutide 5mg (10mg total per vial) studied in clinical research for dual-pathway metabolic regulation. Cagrilintide is a long-acting amylin analog studied for satiety signalling and slowed gastric emptying; Semaglutide is a GLP-1 receptor agonist studied for glucose-dependent insulin secretion and central appetite suppression. Research has examined the pairing for additive effects on weight management and glycaemic control relative to either compound alone.
Blended compound — purity note
Peptide blends are not tested for combined purity as a single compound. However, every component is sourced from the same supplier as our individual peptide products, all of which carry valid Janoshik Analytical COAs. Those certificates apply equally to the same peptides in this blend. View individual COAs →
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties · Cagrilintide
Chemical Properties · Semaglutide
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Cagrilintide
AM833 — Long-Acting Amylin Analog
Cagrilintide (AM833) is a long-acting synthetic analog of amylin — the 37-amino-acid pancreatic hormone co-secreted with insulin by beta cells in response to food intake. Developed by Novo Nordisk for once-weekly subcutaneous dosing, it is in Phase 3 clinical trials in combination with semaglutide under the name CagriSema for obesity and type 2 diabetes.
Amylin acts via calcitonin receptor/RAMP complexes (AMY1, AMY2, AMY3 receptors) expressed in the area postrema, hypothalamus, and nucleus accumbens. Cagrilintide activates these receptors to produce satiety signalling, slow gastric emptying, suppress post-meal glucagon, and reduce food reward — effects mechanistically complementary to and additive with GLP-1R engagement. The GLP-1 and amylin pathways target overlapping but distinct circuits in the hypothalamic satiety network.
Phase 2 SCALE CAGRI data demonstrated dose-dependent weight loss up to 15.6% at 26 weeks for cagrilintide monotherapy. In combination with semaglutide 2.4mg (CagriSema), Phase 2 data showed weight loss exceeding 22% at 32 weeks — superior to either agent alone and approaching the efficacy of bariatric surgery. Phase 3 trials are ongoing for obesity and T2DM.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
